Johnson & Johnson (JNJ) Is Leading The Industry In Cancer Treatments, Says Jim Cramer

We recently published 5 Stocks That Were On Jim Cramer’s Radar As He Discussed AI. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed.

Johnson & Johnson (NYSE:JNJ) is one of the most diversified healthcare companies in the world. The firm operates in the pharmaceutical, medical devices, and other industries. Cramer previously discussed the stock on September 11th, when he wondered whether the major “litigation overhang” surrounding the firm actually involved an “overplayed” hand by the plaintiffs’ lawyers. This time, he was full of praise for Johnson & Johnson (NYSE:JNJ)’s cancer portfolio:

“Well tonight we got JNJ and it’s incredibly important because Joaquin, he does not, he does not do a lot of, he does no interviews, frankly. And I think this is a terrific time because we also have. Look, they’re spending more than 50 billion. I think that they are really at the forefront of building in America. Other than Eli Lilly. So I want to ask about that. Other than that, the stuff that they’re doing against cancer. It’s so incredible. I think we gotta talk about that. I think they are now ahead of everyone, in terms of trying to cure cancer. And I don’t use that word lightly because my ma died of cancer in a horrible fashion, and it’s a cancer that’s been cured since then.”

Johnson & Johnson (JNJ) Is Leading The Industry In Cancer Treatments, Says Jim Cramer

While we acknowledge the potential of JNJ to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JNJ and that has 100x upside potential, check out our report about this cheapest AI stock.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.